1. Home
  2. MEGL vs BGLC Comparison

MEGL vs BGLC Comparison

Compare MEGL & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magic Empire Global Limited

MEGL

Magic Empire Global Limited

N/A

Current Price

$1.28

Market Cap

6.6M

Sector

Finance

ML Signal

N/A

Logo BioNexus Gene Lab Corp Common stock

BGLC

BioNexus Gene Lab Corp Common stock

HOLD

Current Price

$4.40

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEGL
BGLC
Founded
2016
2017
Country
Hong Kong
Malaysia
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
7.8M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
MEGL
BGLC
Price
$1.28
$4.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.7K
280.0K
Earning Date
12-11-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,296,394.00
$9,465,006.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.21
52 Week Low
$1.02
$2.01
52 Week High
$5.52
$15.60

Technical Indicators

Market Signals
Indicator
MEGL
BGLC
Relative Strength Index (RSI) 45.45 40.10
Support Level $1.22 $4.11
Resistance Level $1.34 $4.55
Average True Range (ATR) 0.07 0.27
MACD 0.01 -0.01
Stochastic Oscillator 50.00 33.68

Price Performance

Historical Comparison
MEGL
BGLC

About MEGL Magic Empire Global Limited

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: